Walther Schoenenberger GmbH & Co KG
Pharmaceutical Companies · Böblingen
Walther Schoenenberger GmbH & Co KG is a pharmaceutical company based in Böblingen, Baden-Württemberg, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Walther Schoenenberger GmbH & Co KG Address & Contact
Walther Schoenenberger GmbH & Co KG at a Glance
Walther Schoenenberger GmbH & Co KG from Böblingen is a traditional German pharmaceutical company and a well-known manufacturer of fresh plant juices and herbal medicines. With over 50 years of experience in the industry, the company has established itself as one of the leading providers in this segment. Schoenenberger is particularly known for its fresh plant juices, which are derived directly from fresh medicinal plants and exhibit a particularly bioactive active ingredient matrix. The high-quality products are characterized by their purity and effectiveness, making them especially popular with consumers and professionals.
Services and Products
Schoenenberger produces fresh plant juices from over 25 different medicinal plants, including well-known varieties such as dandelion, nettle, artichoke, and hawthorn. These products are approved as traditional herbal medicines and thus hold a special place in naturopathic therapy. The characteristic cold-pressing method not only ensures the preservation of bioactive enzymes, vitamins, and secondary plant compounds but also the vitality of the raw material. This process prevents important ingredients from being lost due to heat or chemical processes.
- Dandelion: Supports liver and kidney function.
- Nettle: Known for its positive effects on metabolism and skin.
- Artichoke: Promotes digestion and fat digestion.
- Hawthorn: Traditionally used to strengthen the heart and support cardiovascular health.
In addition, Schoenenberger offers a variety of products for specialized applications, such as concentrates to assist with seasonal complaints or special blends to strengthen the immune system. The products are distributed nationally in pharmacies, health food stores, and organic shops and enjoy great popularity due to their natural origin and quality.
Regulatory Classification
As a manufacturer of herbal medicines, Walther Schoenenberger GmbH & Co KG is subject to strict regulatory requirements that relate to production methods and the quality of the products offered. The company complies with the guidelines of the European Medicines Agency (EMA) as well as the German Medicines Act. This ensures that the products are both safe and effective. With the approval as traditional herbal medicines, patients can trust that they receive products that are subject to strict quality controls.
Regional Importance
Böblingen, located in the Stuttgart metropolitan area, offers pharmaceutical manufacturers an attractive environment with well-developed infrastructure and access to qualified professionals. The region is known for its innovative strength and has established itself as an important location for the pharmaceutical industry. Schoenenberger has been a firm part of the naturopathic pharmaceutical world in Baden-Württemberg for decades and thus contributes to the positive economic development of the location. The close cooperation with local universities and research institutions promotes the further development of existing products and research into new therapies.
Special Features of Walther Schoenenberger GmbH & Co KG
A notable characteristic of Walther Schoenenberger GmbH & Co KG is its commitment to sustainability and environmental protection. The company places great importance on ensuring that the raw materials used come from organic farming and are produced under fair conditions. This not only appeals to environmentally conscious consumers but also helps to preserve biodiversity in the cultivation areas. In addition, the entire production chain is regularly checked for its environmental friendliness, contributing to a more transparent and sustainable manufacturing process.
Other pharmaceutical companies: Overview of Pharmaceutical Companies | Pharmaceutical Companies Baden-Württemberg | Pharmaceutical Wholesale
Frequently asked questions about Walther Schoenenberger GmbH & Co KG
What does Walther Schoenenberger do?
Walther Schoenenberger GmbH & Co KG is als sogenanntes Pflanzensaftwerk ein Hersteller of Heilpflanzensäften, Frischpflanzensäften, Frucht- and Gemüsesäften. Die Pflanzensäfte are also in verschiedenen productsn for the Haarpflege verarattet. Außerdem gibt es eine Zusammenstellung of Säften for eine Diätkur.
More Pharmaceutical Companies in Böblingen
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.